Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13878569 | 1.00 | KMT2A (0.53) | KMT2ATACR1EPHX2MDM4TP53 | |
| SCHEMBL13878687 | 0.93 | KMT2A (0.48) | KMT2ATACR1EPHX2MDM4TP53 | |
| SCHEMBL13878650 | 0.93 | KMT2A (0.48) | KMT2ATACR1EPHX2MDM4TP53 | |
| SCHEMBL13878606 | 0.93 | KMT2A (0.48) | KMT2ATACR1EPHX2MDM4TP53 | |
| SCHEMBL4220170 | 0.91 | KMT2A (0.50) | KMT2ATACR1EPHX2CASP3PTPN1 | |
| SCHEMBL13878603 | 0.90 | KMT2A (0.46) | KMT2ATACR1EPHX2MDM4TP53 | |
| SCHEMBL13878685 | 0.90 | PTPN1 (0.48) | KMT2ATACR1EPHX2PTPN1 | |
| SCHEMBL13878661 | 0.90 | KMT2A (0.46) | KMT2ATACR1MDM4TP53 | |
| SCHEMBL13878679 | 0.90 | KMT2A (0.45) | KMT2ATACR1EPHX2PTPN1 | |
| SCHEMBL13878632 | 0.89 | KMT2A (0.51) | KMT2AEPHX2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105091-A1 | Modified Amino Acids | TECHNISCHE UNIVERSITAT WIEN (AT) | 2009-04-23 | — | — | US | disclosed |
| US-20090105091-A1 | Modified Amino Acids | TECHNISCHE UNIVERSITAT WIEN (AT) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105091-A1 | Modified Amino Acids | SLC1A2, NR1H4, OXGR1 | KMT2A 1541/4885TACR1 619/4885EPHX2 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.